The Epigenetic Market was valued at USD 2.15 Billion in 2023 and is estimated to reach USD 6.86Billion by 2033, growing at a CAGR of 12.92 % from 2024 to 2033.
Scope of the market:
Epigenetics is a rapidly and fascinating evolving field within genetics that deals with the study of changes in gene expression or cellular phenotype that do not involve alterations to the underlying DNA sequence. These changes can be heritable and reversible, playing a crucial role in various biological processes, including development, differentiation, aging, and disease.Technological advancement, diseases understanding and therapeutics, and drug development and personalized medicines are the factors that are propelling the epigenetics market to grow during the forecast period.Overall, the interplay between technological innovation, scientific discovery, disease relevance, environmental influences, and ethical considerations shapes the growth and trajectory of the field of epigenetics. As our understanding of epigenetic regulation continues to deepen, so too will the potential for novel applications in medicine, agriculture, and beyond.
Economic Impact of Covid-19:
The COVID-19 pandemic has had both direct and indirect impacts on various industries, including the field of epigenetics. Research interruptions, supply chain disruption, remote work challenges, are the factors that hampered the growth of the market.
However, the COVID-19 pandemic highlighted the importance of understanding host genetics and immune responses to viral infections. This increased focus on immunogenetics and host-pathogen interactions may indirectly benefit certain aspects of epigenetics research, particularly in understanding the epigenetic regulation of immune responses.Investment in Biotechnology and Healthcare and accelerated adoption of digital technologies have shown the positive side during pandemic.
Key Players:
- Illumina Inc
- Merck KGaA
- QIAGENA
- Eisai Co, Ltd
- Thermo Fisher Scientific
- CellCentric
- Syndax
- GeneTex Inc
- EpiGentek Group Inc
- Agilent Technologies Inc
- Element Bioscience Inc
- Abcam plc
- Roche Diagnostics
- Novartis AG
- Dovetail Genomics LLC
- Others
The above key players in the EpigeneticsMarket can be changed according to the client’s requirements.
Moreover, the key players aim towards expansion, joint ventures, collaboration, mergers, and acquisitions to advance capabilities in the Epigenetics Market. In recent years there have been many mergers and acquisitions or closures of the Epigenetics Market.
In October 2023 Germany, Epigenomics AG closed their agreement with New Day Diagnostics LLC which is a US based Diagnostic and contract research company. The closing company has received a cash payment of USD 0.5 million and has paid USD 1 million in December 2023. Furthermore, has to pay USD 0.3 million by June 30th 2024.
Recent Developments in Epigenetics Market.
In 2023: Epigenic joins wave of startups raising cash to edit epigenome.
A China based company a young biotech in a competitive race to use CRISPR tool to altera gene expression without changing its DNA. A breakthrough medicine with the use of hot new gene modulation technology has raised USD 32million. The Epigenic Therapeutics attracted investments from Qiming Venture Partners, OrbiMed and existing investor MorningSide Venture capital in its latest funding round.
Feb 2023: Chroma bags 9-digit financing.
Chroma medicine and its epigenetic-focused tech, with the Cambridge, Massachusetts-based biotech bagging USD 135 million in series B funding.The new fundraising announced which was led by google ventures and including big players in biopharma investment space such as Arch Ventures Partners and Sixth Street. Also, the previous investors such as Sofinnova, Atlas Ventures and Omega Funds who contributed to the round.
Epigenetics Market: Key Benefits:
- The report provides information regarding key drivers, restraints, and opportunities with impact analysis.
- Quantitative and Qualitative analysis of the current market.
- Estimations for the forecast period 2033.
- Historical data and forecast data.
- Recent developments and trends in the market.
- Market share of the market players, company profiles, SWOT analysis, and competitive landscape.
- Covid-19 Impact analysis
Epigenetics Market Segmentation:
By Products:
- Kits
- Enzymes
- Reagents
- Bioinformatic Tools
- Instruments and Consumables
By Application:
- Oncology
- Liquid Tumors
- Solid Tumors
- Non-Oncology
- Immunology
- Cardiovascular Diseases
- Metabolism Diseases
- Development Biology
By Technology:
- Histone Modification
- DNA Methylation
- MicroRNA Modification
- Chromatin Structures
- Others
By End User:
- Pharmaceutical Companies
- Biotechnology Companies
- Research Institutes
- Others
By Region:
Asia-Pacific
- Japan
- China
- India
- Australia
- New Zealand
- Rest of Asia-Pacific
North America
- US
- Canada
- Mexico
Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Europe
The rest of the World
Each of the market segments has been analyzed in detail for market trends, recent trends and developments, drivers, restraints, opportunities, and competitive analysis.
DNA Methylation held the largest share in epigenetics market.DNA methylation is a key epigenetic modification that involves the addition of a methyl group to cytosine nucleotides in DNA, typically occurring at cytosine-guanine (CpG) dinucleotide sites.
Research Scope:
|
Report Scope |
Details |
|
Base Year |
2023 |
|
Historical Years |
2019 to 2022 |
|
Forecast Years |
2024 to 2033 |
|
Market Size 2023 |
USD2.15BN |
|
Market Revenue 2033 |
USD6.86BN |
|
Growth Rate 2024- 2033 |
12.92 % |
|
Report Coverage |
Trends, SWOT Analysis, Competitive Landscape, DROs, Revenue Forecast, PEST Analysis. |
|
Segments Covered |
Products, Application, Technology, End-User, Region |
|
Companies Mentioned |
Illumina Inc, Merck KGaA, QIAGEN, Eisai Co, Ltd, Thermo Fisher Scientific, CellCentric, Syndax, GeneTex Inc, EpiGentek Group Inc, Agilent Technologies Inc, Element Bioscience Inc, Abcam plc, Roche Diagnostics, Novartis AG, Dovetail Genomics LLC |
|
Customization |
Yes |
Regional Analysis:
North America has dominated over other region in 2022 by almost 39% of revenue share. Advanced medical infrastructure, awareness in people, presence of innovative healthcare amenities, highest research and development expenditure, and development in diagnostics process are the factors that support the Epigenetics Market in North America region. Moreover, the increasing investment by key players and rising prevalence of chronic disease for development for epigenetics is boosting the market in this region to grow.
The US Epigenetics Market size was valued at USD 0.59 billion in 2023 and it is expected to reach USD 1.78 by 2032.
Asia-Pacific is expected to grow with the fastest growing region in the forecast period due to significant contributions to scientific research, clinical trials, and technology development underscore its importance in advancing the field of epigenetics on a global scale. Further, the government funding and initiatives for developing the epigenetic reach, involvement of biotechnology and pharmaceutical companies are boosting the market to grow. Moreover, e Asia-Pacific region represents a significant market for molecular diagnostics, including epigenetic-based tests for cancer detection, prognosis, and treatment selection. As healthcare infrastructure and awareness of personalized medicine grow in the region, there is increasing demand for innovative diagnostic technologies. For example, Astellas Pharma, a major pharmaceutical company based in Japan, has been investing in epigenetic drug discovery for cancer and other diseases.
Key questions answered by this report.
- Top market players contributing to the revenue?
- Trending strategies by the players?
- Which region will be the leading one in the forecast period?
- Factors that drive the EpigeneticsMarket?
- Which factors will affect the EpigeneticsMarket?
- How Covid-19 pandemic impacted the growth of the EpigeneticsMarket?
- Which Segment accounted for the EpigeneticsMarket shares?
Frequently Asked Questions (FAQ) :
TOC